09:30 AM EDT, 09/03/2024 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) said Tuesday that its phase 2 SYCAMORE trial of REC-994 in symptomatic cerebral cavernous malformation patients met the primary endpoint of safety and tolerability, showing similar adverse event profiles between REC-994 and placebo.

The 400mg dose indicated trends towards decreased lesion volume and hemosiderin ring size compared to placebo. No significant changes in patient or physician-reported outcomes were observed at the 12-month mark, the company said.

Recursion Pharmaceuticals ( RXRX ) shares fell more than 10% in recent trading activity.

Price: 6.54, Change: -0.74, Percent Change: -10.16